Sherry Knowles, Esq.

Email:  sknowles@kipsllc.com
Phone:  678-694-1390

Sherry M. Knowles is an intellectual property attorney with over 25 years experience in global corporate and private practice. From 2006-2010, Ms. Knowles was the Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, where she served as the worldwide head of patents for all litigation and transactional matters, and managed a global department of over 200 people in 12 offices, including the U.S. (3 offices), Europe (7 offices), China (1 office) and Australia (1 office). At GSK, Ms. Knowles was a member of the Scientific Advisory Board, the Technology Investment Board, the Product Management Board, the Legal Management Team and she led the Global Patents Executive Team.

During her leadership at GSK, the company achieved the successful resolution of patent disputes over Requip, Valtrex, Paxil in Europe, Avodart, the US re-issue of the Advair patent, and a number of Consumer Health, biologics and biopharmaceutical matters. Ms. Knowles had the responsibility for over 1900 pending GSK US applications, over 2200 granted U.S. patents, over 14,000 pending foreign applications and over 15,000 granted foreign patents.

Ms. Knowles played a key role in the case of GlaxoSmithKline and Tafas v. Dudas, 541 F. Supp. 2d 805 (E.D. Va. 2008). On October 9, 2007, GSK became the first and only company in the U.S. to file a lawsuit to challenge the Final Rules published by the U.S. Patent and Trademark Office on August 7, 2007. During the course of litigation, 20 amicus briefs were filed by parties in support of GSK and Dr. Tafas, including from the AIPLA, PhRMA, BIO, IPO, Washington Legal Foundation and CropLife America. The litigation concluded in October 2009, when David Kappos made the decision to withdraw the contested regulations and GSK agreed to join with the PTO in a motion to dismiss all litigation.

In 2008, Managing IP Magazine named Ms. Knowles one of the top 10 most influential people in Intellectual Property, referring to her as a “Patent Owner’s Advocate.”  In 2010, the New Jersey Intellectual Property Lawyers Association awarded Ms. Knowles, as the representative of GSK, the Jefferson Medal for exceptional contribution to Intellectual Property. In 2010, Managing IP Magazine named the GSK Global Patent Team the “In-House IP Team of the Year” for 2009 for the constructive approach to IP in the developing world, the engagement with public policy in Europe and the successful resolution of the USPTO rules matter in the US.

In November 2011, Intellectual Asset Management Magazine listed Ms. Knowles among the top fifty key individuals, companies and institutions that have shaped the IP marketplace in the last eight years. Ms. Knowles is also listed in the IAM 250 “World’s leading IP Strategists,” published by IAM Magazine in 2011.

Ms. Knowles was Chair of the IP Subcommittee of PhRMA in 2008, and Chair Emeritus of the PhRMA IP Subcommittees in 2009 and 2010.  From 2006-2010, she was a member of InterPat, which is the association of Chief Patent Counsels of the major pharmaceutical companies, and from 2008-2010 was a member of the Executive Committee of InterPat.  She was the Chair of the work stream on data exclusivity for InterPat from 2006-2010.

Ms. Knowles has been very active in intellectual property matters in developing countries. Ms. Knowles helped create and headed GSK’s Knowledge Pool for the treatment of neglected tropical diseases in least developed countries. This is the first industry initiative to donate intellectual property, know how and experience to qualified projects via a pool to accelerate capacity building and the development of drugs for commercially neglected diseases. Ms. Knowles led the selection of BIO Ventures for Global Health to be the administrator of the Pool. She also played a leading role in bringing key participants to the Pool, including the Technology Innovation Agency of South Africa. Ms. Knowles executed the Memorandum of Understanding on behalf of GSK with South Africa. She was also instrumental in obtaining the participation of iThemba Pharmaceuticals (a South African emerging company partially funded by the South African government to identify new drugs to treat tuberculosis), and Emory University Institute for Drug Discovery, which focuses on treating the most neglected diseases.

Ms. Knowles led and coordinated the establishment of the GSK’s first patent group in China, located in Shanghai. As part of this initiative, Ms. Knowles’s team provided comments to SIPO (the Chinese Intellectual Property Office) on the draft Third Amendment to the Chinese Patent Law.  Ms. Knowles also met and subsequently corresponded with officials of the SFDA (Chinese Food and Drug Administration) on certain GSK regulatory matters.

In December 2010, Ms. Knowles chaired a conference at the World Bank hosted by The World Bank Legal Vice Presidency on “The Role of Intellectual Property in Development” at its Headquarters in Washington D.C.  The Symposium was organized in collaboration with the Legal Department of the International Finance Corporation (IFC), the Economic Policy and Debt Department of the Poverty Reduction and Economic Management Network (PREM) and the World Bank Science and Technology Innovation Global Expert Team (STI GET).  The Symposium focused on the current debate about the role of intellectual property in development, with the goal to address key issues on how to employ intellectual property in investment and decision making processes to develop legal frameworks which promote economic growth.

In September 2011, Ms. Knowles was a Co-Organizing Chair of a conference in Cape Town South Africa on “Accelerating Innovation and Intellectual Property in South Africa.” The conference brought together global leaders to discuss the unique needs and opportunities involved in creating strong frameworks for innovation and domestic commercial growth in developing countries, and in particular, Africa.

Ms. Knowles is a frequent speaker on legal and policy issues relating to intellectual property, and particularly the pharmaceutical and biotechnology sectors. She has been highlighted in numerous articles. Selected examples of conferences and articles include those listed in a separate attachment. Ms. Knowles is the author of the article “Fixing the Legal Framework for Pharmaceutical Research” Science 327 1083 (2010), and a Response Letter to the Editor, Science 328, 1354 (2010).  She is also the co-author of the articles “Vertical Disintegration in the Pharma Industry-The Role of IP”, Intellectual Asset Management Magazine, Issue 45, Jan/Feb 2011, p. 10-15 and “Robin Hood, the Magna Carta and the European Convention on Human Rights”, Intellectual Asset Management Magazine, Issue 52, March/April 2012.

Prior to working with GlaxoSmithKline, Ms. Knowles spent almost 20 years in private law firm practice. She was a partner in and founder of the Biotechnology and Pharmaceutical Intellectual Property Practice at King & Spalding LLP, where she represented companies, foundations and universities in connection with patent prosecution, litigation, contracts, licensing, financing and other corporate intellectual property issues relating to pharmaceutical, biotechnology and chemical inventions. Ms. Knowles created and defended the patent rights in Emtricitabine (“FTC”), one of the most active drugs for HIV and the cornerstone of the Gilead HIV portfolio, for Emory University, which resulted in monetized royalties to Emory of $540 million. Ms. Knowles also represented Conor Medsystems in connection with a range of litigation over its developmental cardiovascular stent products against Boston Scientific and Angiotech, which helped facilitate Conor’s acquisition by Johnson & Johnson for approx $1.4 billion.

In June 2010, Ms. Knowles left GSK to become the Principal of Knowles Intellectual Property Strategies, LLC, a legal and consulting firm focused on providing global guidance on complex IP matters, obtaining and protecting the full value of innovation, investor support and monetization of assets.

Ms. Knowles received her B.S., cum laude, with distinction in chemistry from Duke University and received her M.S. cum laude in organic chemistry from Clemson University. Prior to attending law school, she spent several years at SmithKline Beecham (now GlaxoSmithKline) as a pharmaceutical synthetic chemist. She received her J.D., magna cum laude, from the University of Georgia where she was a Benjamin Phillips Scholar and was elected to the Order of the Coif.

Selected Articles and Conferences click here